189 related articles for article (PubMed ID: 23284726)
1. Molecular and cellular response profiles induced by the TLR4 agonist-based adjuvant Glucopyranosyl Lipid A.
Lambert SL; Yang CF; Liu Z; Sweetwood R; Zhao J; Cheng L; Jin H; Woo J
PLoS One; 2012; 7(12):e51618. PubMed ID: 23284726
[TBL] [Abstract][Full Text] [Related]
2. IL-18 and Subcapsular Lymph Node Macrophages are Essential for Enhanced B Cell Responses with TLR4 Agonist Adjuvants.
Desbien AL; Dubois Cauwelaert N; Reed SJ; Bailor HR; Liang H; Carter D; Duthie MS; Fox CB; Reed SG; Orr MT
J Immunol; 2016 Dec; 197(11):4351-4359. PubMed ID: 27794001
[TBL] [Abstract][Full Text] [Related]
3. Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, IL-18, and IFN-γ.
Desbien AL; Reed SJ; Bailor HR; Dubois Cauwelaert N; Laurance JD; Orr MT; Fox CB; Carter D; Reed SG; Duthie MS
Eur J Immunol; 2015 Feb; 45(2):407-17. PubMed ID: 25367751
[TBL] [Abstract][Full Text] [Related]
4. Effective Combination Adjuvants Engage Both TLR and Inflammasome Pathways To Promote Potent Adaptive Immune Responses.
Seydoux E; Liang H; Dubois Cauwelaert N; Archer M; Rintala ND; Kramer R; Carter D; Fox CB; Orr MT
J Immunol; 2018 Jul; 201(1):98-112. PubMed ID: 29769270
[TBL] [Abstract][Full Text] [Related]
5. MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant.
Orr MT; Duthie MS; Windish HP; Lucas EA; Guderian JA; Hudson TE; Shaverdian N; O'Donnell J; Desbien AL; Reed SG; Coler RN
Eur J Immunol; 2013 Sep; 43(9):2398-408. PubMed ID: 23716300
[TBL] [Abstract][Full Text] [Related]
6. A TLR4 agonist synergizes with dendritic cell-directed lentiviral vectors for inducing antigen-specific immune responses.
Xiao L; Kim J; Lim M; Dai B; Yang L; Reed SG; Baltimore D; Wang P
Vaccine; 2012 Mar; 30(15):2570-81. PubMed ID: 22314134
[TBL] [Abstract][Full Text] [Related]
7. In vitro evaluation of TLR4 agonist activity: formulation effects.
Misquith A; Fung HW; Dowling QM; Guderian JA; Vedvick TS; Fox CB
Colloids Surf B Biointerfaces; 2014 Jan; 113():312-9. PubMed ID: 24121074
[TBL] [Abstract][Full Text] [Related]
8. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity.
Didierlaurent AM; Morel S; Lockman L; Giannini SL; Bisteau M; Carlsen H; Kielland A; Vosters O; Vanderheyde N; Schiavetti F; Larocque D; Van Mechelen M; Garçon N
J Immunol; 2009 Nov; 183(10):6186-97. PubMed ID: 19864596
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis.
Orr MT; Fox CB; Baldwin SL; Sivananthan SJ; Lucas E; Lin S; Phan T; Moon JJ; Vedvick TS; Reed SG; Coler RN
J Control Release; 2013 Nov; 172(1):190-200. PubMed ID: 23933525
[TBL] [Abstract][Full Text] [Related]
10. Use of protective antigen of Bacillus anthracis as a model recombinant antigen to evaluate toll-like receptors 2, 3, 4, 7 and 9 agonists in mice using established functional antibody assays, antigen-specific antibody assays and cellular assays.
Inglefield J; Catania J; Harris A; Hickey T; Ma Z; Minang J; Baranji K; Spangler T; Look J; Ruiz C; Lu H; Alleva D; Reece JJ; Lacy MJ
Vaccine; 2022 Sep; 40(38):5544-5555. PubMed ID: 35773119
[TBL] [Abstract][Full Text] [Related]
11. Perioperative treatment with the new synthetic TLR-4 agonist GLA-SE reduces cancer metastasis without adverse effects.
Matzner P; Sorski L; Shaashua L; Elbaz E; Lavon H; Melamed R; Rosenne E; Gotlieb N; Benbenishty A; Reed SG; Ben-Eliyahu S
Int J Cancer; 2016 Apr; 138(7):1754-64. PubMed ID: 26453448
[TBL] [Abstract][Full Text] [Related]
12. Intradermally administered TLR4 agonist GLA-SE enhances the capacity of human skin DCs to activate T cells and promotes emigration of Langerhans cells.
Schneider LP; Schoonderwoerd AJ; Moutaftsi M; Howard RF; Reed SG; de Jong EC; Teunissen MB
Vaccine; 2012 Jun; 30(28):4216-24. PubMed ID: 22542815
[TBL] [Abstract][Full Text] [Related]
13. Identification of GLA/SE as an effective adjuvant for the induction of robust humoral and cell-mediated immune responses to EBV-gp350 in mice and rabbits.
Heeke DS; Lin R; Rao E; Woo JC; McCarthy MP; Marshall JD
Vaccine; 2016 May; 34(23):2562-9. PubMed ID: 27085175
[TBL] [Abstract][Full Text] [Related]
14.
Zhang W; Ahmad G; Molehin AJ; Torben W; Le L; Kim E; Lazarus S; Siddiqui AJ; Carter D; Siddiqui AA
J Investig Med; 2018 Dec; 66(8):1124-1132. PubMed ID: 29997146
[TBL] [Abstract][Full Text] [Related]
15. Improved Immune Responses in Young and Aged Mice with Adjuvanted Vaccines against H1N1 Influenza Infection.
Baldwin SL; Hsu FC; Van Hoeven N; Gage E; Granger B; Guderian JA; Larsen SE; Lorenzo EC; Haynes L; Reed SG; Coler RN
Front Immunol; 2018; 9():295. PubMed ID: 29515589
[TBL] [Abstract][Full Text] [Related]
16. A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity in vivo.
Pantel A; Cheong C; Dandamudi D; Shrestha E; Mehandru S; Brane L; Ruane D; Teixeira A; Bozzacco L; Steinman RM; Longhi MP
Eur J Immunol; 2012 Jan; 42(1):101-9. PubMed ID: 22002164
[TBL] [Abstract][Full Text] [Related]
17. The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for TH1 Induction.
Dubois Cauwelaert N; Desbien AL; Hudson TE; Pine SO; Reed SG; Coler RN; Orr MT
PLoS One; 2016; 11(1):e0146372. PubMed ID: 26731269
[TBL] [Abstract][Full Text] [Related]
18. Analytical Characterization of an Oil-in-Water Adjuvant Emulsion.
Sun J; Remmele RL; Sanyal G
AAPS PharmSciTech; 2017 Jul; 18(5):1595-1604. PubMed ID: 27628187
[TBL] [Abstract][Full Text] [Related]
19. Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140.
Arias MA; Van Roey GA; Tregoning JS; Moutaftsi M; Coler RN; Windish HP; Reed SG; Carter D; Shattock RJ
PLoS One; 2012; 7(7):e41144. PubMed ID: 22829921
[TBL] [Abstract][Full Text] [Related]
20. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant.
Coler RN; Bertholet S; Moutaftsi M; Guderian JA; Windish HP; Baldwin SL; Laughlin EM; Duthie MS; Fox CB; Carter D; Friede M; Vedvick TS; Reed SG
PLoS One; 2011 Jan; 6(1):e16333. PubMed ID: 21298114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
